Oregon's state-licensed psilocybin program shows strong real-world outcomes as regulators consider fees that could threaten its survival

Oregon's first peer-reviewed study of a state-licensed, non-medical psilocybin program found encouraging real-world outcomes while the program faces proposed fee increases that operators say could force closures. The cohort followed 346 clients who completed a supervised psilocybin session at 24 service centers between November 2024 and March 2026. At one month, 92.2 percent of 321 respondents reported benefiting, and 58.6 percent ranked the session among the ten most meaningful experiences of their lives. At three months, participants reported reduced moderate to severe depression, anxiety, and PTSD symptoms and improved wellbeing, with 90 percent of the original cohort providing follow-up data. Four participants experienced serious adverse behavioral reactions, while the researchers identified inexperience, psychological vulnerability, and higher doses as possible risk factors. The findings are limited because the study had no control group, relied on self-selected clients, and cannot separate psilocybin effects from preparation, facilitation, or integration support. The evidence may inform other states, but Oregon's proposed fees could undermine the system that produced it.